hVIVO confirms phase 1 trial of AGS-v PLUS for mosquito-borne diseases
Category: #health  By Pankaj Singh  Date: 2019-08-02
  • share
  • Twitter
  • Facebook
  • LinkedIn

hVIVO confirms phase 1 trial of AGS-v PLUS for mosquito-borne diseases

This clinical study will assess the safety and immunogenicity of vaccine when given with or without adjuvant to small cohorts of healthy subjects.

hVIVO plc has reportedly announced that AGS-v PLUS, an investigational vaccine created to protect against several different mosquito-borne diseases, will be examined in a phase 1 clinical trial. The phase 1 trial will be conducted by the NIH at the University of Maryland School of Medicine. AGS-v PLUS vaccine was developed by Imutex Limited which is 49 percent joint venture of hVIVO with the SEEK Group. The study has received additional funding from the UK Department of Health and Social Care which is managed by Innovate UK.

Apparently, AGS-v PLUS has been created to activate an immune reaction to the proteins in mosquito saliva, which can hold many diverse pathogens, such as Malaria and Zika. This clinical study will assess the safety and immunogenicity of vaccine when given with or without adjuvant to small cohorts of healthy subjects. The vaccine may also contain a mosquito control element. The study will gather data on the mosquitoes’ fertility which feed on vaccinated volunteers.

Seemingly, the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, has earlier tested a previous version of AGS-v vaccine in a first-in-human trial. The trial was organized in NIAID’s Laboratory of Infectious Diseases’ Special Clinical Studies Unit at the NIH Clinical Center in Bethesda, Maryland. The final outcomes of this trial are expected in due course.

Trevor Phillips, Executive Chairman, hVIVO, has reportedly stated that the company is pleased to see the association with NIH and the University of Maryland School of Medicine remains as AGS-v PLUS, one of the assets in the joint venture Imutex, transfers into the clinic. The company is delighted that the asset development has been ongoing with NIAID-funded researchers analyzing the vaccine and extra funding for the trial by Innovate UK, he further added.

 

Source credit: https://imutex.com/wp-content/uploads/2019/07/AGS-v_PLUS_Phase_1_FINAL.pdf



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...